Stock AnalizNational Vision Holdings, Inc. EYE
Ophthalmic Goods · IPO 2017 · data as of November 13, 2026
National Vision Holdings, Inc. (EYE) is a healthcare company listed in the US with a market value of about $1.4B. In the twelve months to October 3, 2026 it had revenue of $2.1B and net income of $66M, a net margin of 3.2%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is financial health (3/5); the weakest is track record (0/5).
Key numbers: a P/E of 22.0, a price to free cash flow of 21.0, 5-year revenue growth of 3% a year, a 5-year average ROIC of 3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 37% below the current price.
Score: 1.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Positive free cash flow
- Interest covered more than 5 times
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.1B | $2.0B | $1.8B | $1.8B | $1.6B | $2.1B | $1.7B | $1.7B | $1.5B | $1.4B | $1.2B |
| Net income | $66M | $30M | -$28M | -$66M | $42M | $128M | $36M | $33M | $24M | $43M | $13M |
| Free cash flow | $68M | $73M | $38M | $58M | $6M | $163M | $158M | $64M | $2M | -$3M | $8M |
| EPS (diluted) | $0.83 | $0.37 | $-0.36 | $-0.84 | $0.52 | $1.43 | $0.44 | $0.40 | $0.30 | $0.70 | $0.23 |
| Net margin | 3.2% | 1.5% | -1.6% | -3.8% | 2.6% | 6.2% | 2.1% | 1.9% | 1.5% | 3.1% | 1.1% |
| ROIC | — | 2.7% | -0.5% | 1.1% | 2.0% | 8.0% | 4.3% | 3.4% | 2.5% | 4.2% | 3.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $27.00, 48% above the current price; targets range from $20.00 to $35.00; the consensus rating is “Buy”; expected EPS is $1.00 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is National Vision’s P/E ratio?
About 22.0, based on the last twelve months of diluted earnings per share (forward P/E about 21.1).
Is National Vision stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 37% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does National Vision pay a dividend?
Not currently.
Is National Vision a good stock to buy?
We do not give buy or sell advice. National Vision scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.